SCHEMBL5407353

SCHEMBL5407353

O=c1c2ccc3occcc3c2nc2ccc3ccccc3c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.44
PTPN1 P18031 2/20 0.44
TYMS P04818 2/20 0.43
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ABCG2 Q9UNQ0 3/20 0.37
KDM4E B2RXH2 2/20 0.36
ESR1 P03372 1/20 0.36
HTT P42858 1/20 0.36
AHR P35869 2/20 0.36
MAOA P21397 2/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
FYN P06241 1/20 0.36
MAPK3 P27361 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6708105 0.81 ALDH1A1 (0.43) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL5229303 0.80 KDM4E (0.40) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL3295735 0.77 ALDH1A1 (0.37) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL4495841 0.75 MAPK10 (0.42) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL29588824 0.75 MAPK10 (0.42) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL118020 0.71 MAOA (0.40) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL9311258 0.70 GAA (0.40) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL4501863 0.68 CDK4 (0.44) POLBKMT2AMEN1ALDH1A1MAPT
Cinnamic Acid SCHEMBL5929391 0.68 HCAR2 (0.39) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL4892024 0.68 CDK4 (0.41) POLBKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7276512-B2 Benzo[a]pyrano[3,2-h]acridin-7-one compounds LES LABORATOIRES SERVIER (FR) 2007-10-02 US disclosed
CN-1289502-C New derivatives of benzo[a]pyrano[3,2-h]acridin-7-one, a process for their preparation and pharmaceutical compounds containing them SERVIER LAB (FR) 2006-12-13 CN disclosed
CN-1576277-A New derivatives of benzo[a]pyrano[3,2-h]acridin-7-one, a process for their preparation and pharmaceutical compounds containing them SERVIER LAB (FR) 2005-02-09 CN disclosed
US-20040266753-A1 Benzo[a]pyrano[3,2-h]acridin-7-one compounds LES LABORATOIRES SERVIER (FR) 2004-12-30 US disclosed
EP-1491544-A1 Benzo[a]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof Les Laboratoires Servier (FR) 2004-12-29 EP disclosed
EP-1491544-A1 Benzo[a]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof Les Laboratoires Servier (FR) 2004-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266753-A1 Benzo[a]pyrano[3,2-h]acridin-7-one compounds CBR1, AHR, AR POLB 849/4885PTPN1 642/4885TYMS 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.